KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial.

Josef S Smolen, Ted R Mikuls, James Galloway, Ulf Müller-Ladner, Jeffrey R Curtis, Motomu Hashimoto, Tsutomu Takeuchi, Ernest Choy, Yoshiya Tanaka, Carlos Cara, Bernard Lauwerys, Nicola Tilt, Baran Ufuktepe, Peter C Taylor

RMD Open 12(1) e006094

PMID41617358
PMCIDPMC12887508
DOI10.1136/rmdopen-2025-006094
发表日期2026-01-30
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图。
摘要

摘要

OBJECTIVES: To assess the impact of rheumatoid factor (RF) levels and previous inadequate responses/intolerance to tumour necrosis factor inhibitors (TNFi-IR) on the efficacy of certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) through a post hoc analysis of the RA Evaluation in Subjects Receiving TNF Inhibitor CZP (REALISTIC) trial. METHODS: In the phase IIIb REALISTIC trial, patients with RA were randomised to CZP (400 mg at weeks 0, 2 and 4, then 200 mg every 2 weeks) or placebo (PBO) for 12 weeks, followed by open-label CZP (minimum 16 weeks). Outcomes reported to week 36 include Disease Activity Score 28 C-reactive protein (DAS28-CRP) and Clinical Disease Activity Index (CDAI) scores, rates of DAS28-CRP <2.6 and CDAI remission (CDAI ≤2.8) and components of each. Data were stratified by baseline RF level (≤3rd quarter (≤Q3; <180 kU/L) vs 4th quarter (Q4; 'high RF'; ≥180 kU/L)) and prior TNFi use (TNFinaïve vs TNFi-IR). RESULTS: A total of 930 patients were included: 751 CZP-randomised and 179 PBO-randomised. At week 12, CZP-randomised patients experienced marked and similar improvements in disease activity, irrespective of RF level and prior TNFi use, while PBO-randomised patients did not. Responses generally improved through week 36 in CZP-treated patients (including PBO-randomised switchers), with similar efficacy across subgroups. CONCLUSIONS: Patients with high and low RF levels experienced similar clinical responses to CZP treatment, irrespective of previous inadequate responses or intolerance to TNFis. These findings expand previous observations, supporting CZP as an effective treatment for patients with RA who have high RF levels and prior inadequate responses to TNFis. TRIAL REGISTRATION NUMBER: NCT00717236.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 128-joint Disease Activity Score C reactive protein (DAS28-CRP) and Clinical Disease Activity Index (CDAI) in (a) inadequate response or intolerance to tumour necrosis factor inhibitors (TNFi-IR) patients, (b) TNFi-naïve patients and (c) overall population, stratified by rheumatoid factor (RF) level (<180 kU/L (≤Q3) vs ≥180 kU/L (Q4)) (observed case). Data are reported (as mean [95% confidence interval]) to Week 12 for PBO-randomised patients and Week 36 for CZP-treated patients, including those who switched from PBO to open-label CZP from Week 12. CZP, certolizumab pegol; PBO, placebo; Q2W, every 2 weeks; Q3, third quarter; Q4, fourth quarter.
非 KM Figure
Figure 2Rates of 28-joint Disease Activity Score C reactive protein (DAS28-CRP) <2.6 and Clinical Disease Activity Index (CDAI) remission (CDAI ≤2.8) in (a) inadequate response or intolerance to tumour necrosis factor inhibitors (TNFi-IR) patients, (b) TNFi-naïve patients and (c) overall population, stratified by rheumatoid factor (RF) level (<180 kU/L (≤Q3) vs ≥180 kU/L (Q4)) (observed case). Data are reported to Week 12 for PBO-randomised patients and Week 36 for CZP-treated patients, including those who switched from PBO to open-label CZP from Week 12. CDAI remission defined as CDAI ≤2.8. CDAI: Clinical Disease Activity Index; CZP, certolizumab pegol; PBO, placebo; Q2W, every 2 weeks; Q3, third quarter; Q4, fourth quarter.
非 KM Figure